journal
MENU ▼
Read by QxMD icon Read
search

Innovations in Clinical Neuroscience

journal
https://www.readbyqxmd.com/read/29344427/top-10-myths-about-telepsychiatry
#1
Donna Vanderpool
This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS, Inc. (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation, education and onsite risk management audits, and other resources to healthcare providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company...
September 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29344426/zika-microcephaly
#2
Murali K Kolikonda, Kavitha Srinivasan, Manasa Enja, Vishwanath Sagi, Steven Lippmann
No abstract text is available yet for this article.
September 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29344425/a-case-of-psychosis-in-a-patient-with-secondary-adrenal-insufficiency-a-possible-etiological-role-of-a-hypocortisolemic-induced-increase-in-proinflammatory-cytokines
#3
David R Spiegel, Aaron B Nelson, David C Lieb, Alexander M Pattison, Justin Smith, Patrice Zigrossi, Erin Godbout
Adrenal insufficiency is divided into three types based on the etiology of its development. In primary adrenal insufficiency, pathology resides in end-organ failure at the level of the adrenal cortex, while in secondary and tertiary adrenal insufficiency, impairment rests in the pituitary gland and hypothalamus, respectively. Regardless of etiology, adrenal insufficiency results in a hypocortisolemic condition. While the relationship between neuropsychiatric symptoms, especially psychosis, and hypercortisolemia has been extensively documented, the development of hypocortisolemia-induced psychosis is less common...
September 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/29344424/letters-to-the-editor
#4
Sriram Ramaswamy, David Driscoll, Lynette M Smith
No abstract text is available yet for this article.
September 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28979826/what-can-i-do-about-a-negative-online-review
#5
Donna Vanderpool
This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS, Inc. (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation, education and onsite risk management audits, and other resources to healthcare providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company...
May 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28979825/it-s-time-for-combination-therapies-in-multiple-sclerosis
#6
EDITORIAL
Jagannadha Avasarala
The treatment of multiple sclerosis continues to evolve. However, even with the introduction of B-cell depleting monoclonal antibodies, disability progression continues unabated since B-cell therapies are unable to cross the blood brain barrier and thus are unable to address the disease that lurks within the brain. In this commentary, the author explores the research and practice of using B-cell depleting monoclonal antibody therapies in MS. The author provides discussion on the blood brain barrier as the primary limitation to the effectiveness of MS therapies...
May 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28979824/when-the-opioid-medications-go-missing-confidentiality-and-safety-in-adolescents
#7
Muhammad Hassan Majeed
Patients receiving end-of-life or palliative care usually possess an ample supply of opioid pain medications to help alleviate their pain. The risk of these drugs being diverted is high because such patients often have an excess of these medications, and because they are typically unable to manage medications themselves. For example, adolescents might steal these medications for recreational use. The author presents a case in which a minor admitted stealing and using opioid pain medication belonging to her mother, who was in hospice home care...
May 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28979823/single-nucleotide-polymorphisms-and-the-central-nervous-system-potential-biomarkers-in-identifying-suicide-risk
#8
REVIEW
Atmaram Yarlagadda, Kevin P Rosenblatt, Anita H Clayton
The rate of completed suicides continues to rise across nations, cultures, socioeconomic classes, age groups, sexes, military personnel, veterans, and civilians from different backgrounds. Most concerning is the absence of diagnosed mental health disorders in the majority of these cases, per current literature reports. Efforts in the identification and possible prevention of this ultimate, tragic act of self-destruction have been minimally successful. In this article, the authors discuss the possible biological mechanisms including the role for potential markers, single nucleotide polymorphisms (SNPs), and their association with suicidal behaviors...
May 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28979822/the-role-and-treatment-implications-of-peripheral-and-central-processing-of-pain-pruritus-and-nausea-in-heightened-somatic-awareness-a-review
#9
REVIEW
David R Spiegel, Alexander Pattison, Alexis Lyons, Umer Ansari, Aidan L Mccroskey, Eric Luehrs, Lauren Barr, Stephanie Le
Pain, pruritus, and nausea are complex sensory and emotional physiological symptoms that can vary widely between people and even within an individual, depending on the context and meaning of the symptom and the psychological state of the person. This article reviews the acute neural transmission of pain, pruritus, and nausea symptoms, which can begin in the periphery and/or viscera. The subsequent multiple pathways in the central nervous system that become involved in the processing of these symptoms are also discussed...
May 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28584697/managing-your-aging-patient-population
#10
Ann L McNary
This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS, Inc. (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation, education and onsite risk management audits, and other resources to healthcare providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company...
March 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28584696/redefining-acute-relapses-in-multiple-sclerosis-implications-for-phase-3-clinical-trials-and-treatment-algorithms
#11
EDITORIAL
Jagannadha Avasarala
Relapses in multiple sclerosis are defined as periods of clinical worsening and radiological progression. Magnetic resonance imaging data, however, are not always supportive of "clinical worsening," and clinical symptoms of worsening may not always be present in cases of acute relapse. In the pharmaceutical domain, this discordance between "clinical worsening" and "radiological progression" has never been fully elucidated, and no Phase 3 clinical study has addressed this conundrum. Thus, the true number of acute relapse cases enrolled in Phase 3 clinical studies remains unclear...
March 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28584695/neuroendocrine-autonomic-and-metabolic-responses-to-an-orexin-antagonist-suvorexant-in-psychiatric-patients-with-insomnia
#12
Masaru Nakamura, Takahiko Nagamine
Aim: The aim of this study was to investigate the neuroendocrine, autonomic, and metabolic system responses to suvorexant in psychiatric subjects with insomnia. Design: This prospective study was conducted in Kusatsu Hospital in Hiroshima, Japan and included 40 psychiatric inpatients treated with suvorexant from December 2014 to April 2016. Methods: Questionnaire of Pittsburgh Sleep Quality Index (PSQI), Generalized Anxiety Disorder-7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9) scores were checked at baseline, Week 2, and Week 4, and fasting serum levels of prolactin, insulin, cortisol, noradrenaline, white blood cell count, and average pulse rate were measured at baseline and Week 4 and Week 8 after suvorexant initiation...
March 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28584694/liothyronine-for-depression-a-review-and-guidance-for-safety-monitoring
#13
REVIEW
Katie T B Touma, Allysa M Zoucha, Jonathan R Scarff
Objective: The objective of this review is to discuss triiodothyronine's (T3, liothyronine) mechanism of action, efficacy in enhancement and augmentation trials, and dosing and safety considerations for the treatment of depression. Method: A literature search of PubMed was performed using search terms depression, augmentation, antidepressant, and liothyronine. Only English-language studies of subjects with unipolar depression were included from the past 50 years. Results: Most studies have shown that liothyronine is an efficacious enhancement and augmentation strategy for depression in combination with antidepressants, primarily tricyclic antidepressants and selective serotonin reuptake inhibitors...
March 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28584693/interactive-voice-response-and-text-based-self-report-versions-of-the-electronic-columbia-suicide-severity-rating-scale-are-equivalent
#14
Chad Gwaltney, James C Mundt, John H Greist, Jean Paty, Brian Tiplady
Objectives: Our study objective was to compare the equivalence of a new version of the electronic Columbia-Suicide Severity Rating Scale that was administered on a tablet device with the existing interactive voice response version in order to support the prospective monitoring of suicidal ideation and behavior in clinical trials and clinical practice. Design: This was a randomized, crossover-equivalence study with no treatment intervention. Setting: The study setting was a psychiatric hospital. Participants: Fifty-eight recently admitted psychiatric inpatients and 28 employees of the hospital site were included in the study...
March 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28584692/human-embryonic-stem-cells-in-the-treatment-of-autism-a-case-series
#15
Geeta Shroff
Background: Autism spectrum disorder is a neurodevelopmental disorder accompanied by weak immune system and neuroinflammation. Multiple factors contribute to etiology of autism spectrum disorder including genetic disorders, environmental substances/toxins, imbalanced immune system, encephalitis, and viral infections. Autism spectrum disorder is an incurable disease; however, it can be managed by educational and medical interventions. Human embryonic stem cell therapy has been shown to improve blood perfusion in the brain; thus, this therapy may be effective in improving motor skills, social skills, and cognition in patients with autism spectrum disorder...
March 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28584691/modafinil-augmentation-therapy-in-patient-with-traumatic-brain-injury
#16
Oleg V Tcheremissine, James C Rachal
No abstract text is available yet for this article.
March 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28409061/severe-hypoglycemia-associated-with-tiapride-in-an-elderly-patient-with-diabetes-and-psychosis
#17
Takahiko Nagamine
No abstract text is available yet for this article.
January 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28386523/risk-management-issues-when-taking-locum-tenens-assignments
#18
Charles D Cash
This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS, Inc. (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation, education and onsite risk management audits, and other resources to healthcare providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company...
January 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28386522/ketamine-therapy-for-treatment-resistant-depression-in-a-patient-with-multiple-sclerosis-a-case-report
#19
Michael M Messer, Irina V Haller
Objective: Depression is a common condition among patients with multiple sclerosis and often becomes resistant to oral antidepressants. We report a patient with multiple sclerosis who developed severe treatment-resistant depression and who was successfully treated with intravenous ketamine over the period of two years. Methods: Ketamine treatment protocol included an initial series of six treatments administered every other day, followed by a maintenance schedule. Ketamine was administered intravenously at 0...
January 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28386521/micrornas-as-biomarkers-for-psychiatric-conditions-a-review-of-current-research
#20
REVIEW
Anoop Narahari, Mariyah Hussain, Venkatesh Sreeram
Neural-derived exosomes can be used as diagnostic markers to screen for various psychiatric conditions. These intravenously injected exosomes carry the potential to cross the blood brain barrier and deliver miRNA molecules specifically to neurons, microglia, and oligodendrocytes in the brain, resulting in specific gene knockdown. Here the authors review and discuss the current research on microRNA molecules and the therapeutic roles they may potentially play in treating depression, bipolar disorder, and schizophrenia...
January 2017: Innovations in Clinical Neuroscience
journal
journal
43359
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"